Corbus Pharmaceuticals Holdings, Inc. Stock
Equities
CRBP
US21833P3010
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.5 USD | -5.74% | -8.29% | +454.64% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 352M |
---|---|---|---|---|---|
Net income 2024 * | -53M | Net income 2025 * | -65M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.44
x | P/E ratio 2025 * |
-6.54
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.31% |
Latest transcript on Corbus Pharmaceuticals Holdings, Inc.
1 day | -5.74% | ||
1 week | -8.29% | ||
Current month | -14.63% | ||
1 month | -5.98% | ||
3 months | +296.92% | ||
6 months | +485.66% | ||
Current year | +454.64% |
Managers | Title | Age | Since |
---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Sean Moran
DFI | Director of Finance/CFO | 66 | 14-04-10 |
Chief Tech/Sci/R&D Officer | 50 | Feb. 27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Holmer
CHM | Chairman | 74 | 13-12-31 |
Avery Catlin
BRD | Director/Board Member | 75 | 14-07-31 |
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 33.5 | -5.74% | 142,333 |
24-04-24 | 35.54 | -5.83% | 221,002 |
24-04-23 | 37.74 | +0.11% | 500,521 |
24-04-22 | 37.7 | -3.92% | 94,730 |
24-04-19 | 39.24 | +7.42% | 283,601 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+454.64% | 352M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.79% | 22.02B | |
-17.84% | 20.9B | |
-11.11% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- CRBP Stock